Dr. Anil Abraham Joy, MD, FRCPC

Dr. Joy currently serves as a Professor of Oncology. Division of Medical Oncology, Faculty of Medicine and Dentistry at the University of Alberta and also as a staff Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta.

Dr. Joy currently serves as a Professor of Oncology. Division of Medical Oncology, Faculty of Medicine and Dentistry at the University of Alberta and also as a staff Medical Oncologist at the Cross Cancer Institute in Edmonton, Alberta.
 
He received his Bachelor of Science Degree (Honours with Distinction, Specialization in Pharmacology) and Medical Doctorate (Honours with Distinction) from the University of Alberta.  He is certified by the Royal College of Physicians and Surgeons of Canada as a specialist in Internal Medicine with subspecialty certification in Medical Oncology.  
His primary oncologic care interests include Breast and Thoracic Malignancies. He is actively involved in patient care, clinical research, medical education, cancer survivorship/well-being, cancer advocacy and global/regional oncology disparity issues and has multiple peer-reviewed publications in these areas.
He is actively involved with the Canadian Clinical Trials Group, and serves as National Chair for the CCTG MA.38 metastatic breast cancer clinical trial.

His former appointments include serving on the Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer, past Chair of the Northern Alberta Breast Cancer Program, Medical Director (Edmonton) of the Alberta Cancer Research Biobank (former CBCF Tumor Bank), pan-Canadian Working Group on Primary Care and Oncology Care Integration (Canadian Partnership Against Cancer) as well as Provincial Chair of the Alberta Breast Cancer Program. He currently serves on the pan-Canadian Oncology Drug Review (pCODR) Canadian Agency for Drugs and Technologies in Health (CADTH) on the Expert Review Committee (pERC) where they assess the clinical evidence and cost-effectiveness of cancer drugs in order to make recommendations to help guide drug funding decisions across Canada.